BIO-Europe: The FDA decision date for Hansa's IgG-inactivating therapy for kidney transplant patients is coming up on December 19th
CEO Renée Aguiar-Lucander describes the unmet need for a therapy like this, and discusses how Hansa has been preparing for this decision date well in advance.
Coverage brought to you by










.png)
